Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome

American Journal of Ophthalmology

Volumn 136, Issue 4, 2003, Pages 739-741

  Rechtman, Ehud ^a,b   Allen, Valerie D ^a   Danis, Ronald P ^a,c   Pratt, Linda M ^a   Harris, Alon ^a   Speicher, Matthew A ^a  

^a INDIANA UNIVERSITY   (United States)

^b KAPLAN MEDICAL CENTER   (Israel)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; CASE REPORT; CATARACT; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; OCULAR HISTOPLASMOSIS; PRIORITY JOURNAL; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME;

EID: 0141793688     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(03)00389-1     Document Type: Article

References (4)

1. Fine S.L., Wood W.J., Isernhagen R.D., Singerman L.J., Bressler N.M., Folk J.C., et al. Laser treatment for subfoveal neovascular membranes in ocular histoplasmosis syndrome results of a pilot randomized clinical trial . Arch Ophthalmol. 111:1993;19-20.
2. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1994;112:500-509.
3. Saperstein D.A., Rosenfeld P.J., Bressler N.M., et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome one-year results of an uncontrolled, prospective case series . Ophthalmology. 109:2002;1499-1505.
4. Martidis A., Miller D.G., Ciulla T.A., Danis R.P., Moorthy R.S. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocul Pharmacol Ther. 15:1999;425-428.